

Oncodesign has appointed Karine Lignel as Group Chief Development Officer

Paris and Dijon (France), October 25, 2021 – 18:00 CEST – ONCODESIGN (ALONC – FR0011766229), a biopharmaceutical group specializing in precision medicine, is announcing the appointment of Karine Lignel as Senior Executive Vice President - Group Chief Development Officer.

“We are honored and proud to welcome Karine Lignel to our ranks. She knows our company well, as she has stood alongside and supported it with great commitment through her role as administrator, representing Crédit Mutuel Innovation since 2008,” said Philippe Genne, Founder, Chairman and Chief Executive Officer of Oncodesign. “Her skills in venture capital – where she has excelled for more than 20 years in biotechnology and finance – combined with her in-depth knowledge of the company and its strategy will help us accelerate our development in a major and tangible way. We planned to accelerate external growth by acquiring companies, technologies and complementary products in line with our objectives. At the meeting point of these skills, Karine Lignel’s new role is a very strong asset for Oncodesign, and we are fully confident that she will succeed in her mission.”



Karine Lignel, new Group Chief Development Officer at Oncodesign, adds:

“I am delighted to be joining Oncodesign in an operational role. I have known the company and its leaders for a very long time, and have always admired their objectives and ways of operating. In my role as shareholder representative, I witnessed the tremendous development of Oncodesign, and I am proud to now be able to work with them even more closely, bringing my own development and strategy skills. Playing a part in the discovery of new therapies, particularly for cancer, is such an important mission for me, and it means that I will be fully committed and highly motivated.”

Karine Lignel, 53 years old, is the former President of Crédit Mutuel Innovation (€250 million of equity dedicated to investments in innovative companies), a subsidiary of Crédit Mutuel Equity. Over the course of her career, she has monitored and participated in the development of more than 60 tech companies, mainly in health, including Nanobiotix, Tissium, Maat Pharma, Endodiag, and Global Bioenergies.

Before her more than twenty-year career in venture capital that she began at Créagro, Karine Lignel had held technical and managerial positions in the industry, in particular at Barry Callebaut.

As an ENSIA (AgroParisTech) engineer, Karine Lignel holds a Master’s degree in Management and Finance from the IGIA, as well as administrator certification from the ESSEC business school.

About Oncodesign: www.oncodesign.com

Oncodesign is a biopharmaceutical company specializing in precision medicine, founded in 1995 by its current CEO and majority shareholder. It has been listed on the Euronext Growth Market since April 2014. Its mission is to discover effective therapies to fight cancer and other diseases without a therapeutic solution. With its unique experience, enriched thanks to over 1,000 customers – including the world’s largest pharmaceutical companies – and based on a one-of-a-kind technological platform combining artificial intelligence, medicinal chemistry, pharmacology, regulatory bioanalysis and cutting-edge medical imaging, Oncodesign is able to select new therapeutic targets, then design and develop potential preclinical candidates up to the clinical phase stage. Oncodesign has configured its organization to offer innovative services to its customers and licenses for its proprietary molecules. When applied to kinase inhibitors – molecules that represent a market estimated to be worth more than \$65 billion by 2027 and nearly 25% of R&D investments in the pharmaceutical industry – Oncodesign’s technology has already made it possible to target several molecules of interest with a high therapeutic potential, both in and outside of oncology, and has signed partnerships with international pharmaceutical groups. Based in Dijon, France, at the heart of the University Hospital complex as well as the Paris-Saclay complex, Oncodesign boasts 230 employees across three Business Units (BU) – Service, Biotech, and Artificial Intelligence – and has subsidiaries in Canada and the United States.



oncodesign.com

contacts

Oncodesign


Philippe Genne
Chairman and Chief Executive
Officer Tel.: +33 (0)380,788,260
investisseurs@oncodesign.com

NewCap

Investor Relations
Mathilde Bohin / Louis-Victor
Delouvrier Tel.: +33 (0)144 719495
oncodesign@newcap.eu

NewCap

Media Relations
Arthur Rouillé
Tel.: +33 (0)144,710,015
oncodesign@newcap.eu



Disclaimer

This document contains forward-looking statements and estimates regarding the financial position, results of operations, strategy, projects and future performance of the Company and the market in which it operates. Some of these statements, forecasts and estimates may be recognized by the use of words such as, without limitation, “believe”, “anticipate”, “predict”, “expect”, “project”, “plan”, “intend”, “estimate”, “may”, “want”, “continue” and similar expressions. These include all questions that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors that were considered reasonable when made but may not prove to be correct. Actual events are difficult to predict and may depend on factors beyond the control of the Company. Accordingly, the Company’s actual results, financial conditions, performance or achievements, or industry results, may differ materially from future results, performance or achievements as expressed or implied by such statements, forecasts and

estimates. In light of these uncertainties, no representation is made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. In addition, forward-looking statements, forecasts and estimates are only valid as of the date of publication of this document. The Company disclaims any obligation to update such forward-looking statements, forecasts or estimates to reflect any change in the Company’s expectations relating thereto, or any change in the events, conditions or circumstances on which such statements, forecasts or estimates are based, except as required by French law.